Intersect ENT (NASDAQ: XENT) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Intersect ENT to related companies based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.
Valuation & Earnings
This table compares Intersect ENT and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Intersect ENT||$78.71 million||-$25.22 million||-46.13|
|Intersect ENT Competitors||$1.03 billion||$127.56 million||209.18|
Intersect ENT’s rivals have higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and price targets for Intersect ENT and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intersect ENT Competitors||204||1195||2670||86||2.63|
Intersect ENT currently has a consensus price target of $30.57, indicating a potential upside of 6.89%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.19%. Given Intersect ENT’s rivals higher possible upside, analysts clearly believe Intersect ENT has less favorable growth aspects than its rivals.
Institutional and Insider Ownership
80.2% of Intersect ENT shares are owned by institutional investors. Comparatively, 67.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 13.7% of Intersect ENT shares are owned by company insiders. Comparatively, 11.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Intersect ENT and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intersect ENT Competitors||-119.88%||-41.90%||-10.84%|
Volatility & Risk
Intersect ENT has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Intersect ENT’s rivals have a beta of 1.07, suggesting that their average stock price is 7% more volatile than the S&P 500.
Intersect ENT Company Profile
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.